The Globe and Mail reports in its Friday, Feb. 6, edition that Ventum Capital analyst Rob Goff has reaffirmed his "buy" rating for Healwell AI. The Globe's David Leeder writes in the Eye On Equities column that Mr. Goff trimmed his share target to $2.75 from $3.75. Analysts on average target the shares at $3.34. Mr. Goff says in a note: "We await visible evidence of revenue and platform synergies expected to emerge as the year progresses. We remain confident that both aspects will emerge across the year. However, we are taking a more conservative approach: rewarding as results confirm benefits. ... Our bullish thesis remains unchanged as we look for sustained outperformance given the company's AI-leveraged growth profile. Healwell AI's growth prospects are driven by its AI-powered patient identification and prognostic care solutions delivered by its integrated electronic health records patient care software. The integrated data and service capabilities are strengthened by its global distribution and alignment with WELL Health, which offers access to 30 per cent of Canadian clinics and a strong U.S. network. The complementary services ensure significant cross-selling opportunities and enhanced capabilities."